Ongoing Project

Histone Demethylases in Cancer Cell Plasticity

Ongoing Project

Histone Demethylases in Cancer Cell Plasticity

Cancer stem cells are intrinsically resistant to most therapies. Through a collaboration with leading synthetic chemists, we are investigating and developing compounds that selectively eliminate cancer stem cells through non-apoptotic mechanisms.

Collaborators

Dr. Michael Lewis, Baylor College of Medicine

Josh Newby, Patient Advocate

Regulators of Histone Methylation Facilitate EMT Reversal

Histones are proteins which facilitate the condensation of DNA in the nucleus. Tight regulation of the accessibility of the DNA is essential for appropriate gene expression. One mechanism underlying this is the post-translational modification of histones, termed the histone code. We have demonstrated that EMT drives genome-wide changes in the histone methylation landscape and that these changes underlie the changes in expression of thousands of genes (Malouf and Taube et al. 2013) and that a histone demethylase is responsible for remodeling bivalency across the genome in cancer stem cells (Taube and Sphyris et al. 2017). We are working to characterize the specific roles of proteins which ‘write’ the histone code, proteins which ‘read’ the histone code, and proteins that ‘erase’ the histone code in epithelial-mesenchymal plasticity.

Funded by Susan G. Komen #CCR18548469

Interested in more Projects?